Core Laboratories N.V. (CLB) : Shelter Ins Retirement Plan added new position in Core Laboratories N.V. during the most recent quarter end. The investment management firm now holds 27,500 shares of Core Laboratories N.V. which is valued at $3.2 Million , the company said in a statement filed on May 13, 2016 with the SEC.Core Laboratories N.V. makes up approximately 1.50% of Shelter Ins Retirement Plan’s portfolio.
Other Hedge Funds, Including , Ubs Oconnor sold out all of its stake in CLB during the most recent quarter. The investment firm sold 9,100 shares of CLB which is valued $1.1 Million.Cipher Capital Lp boosted its stake in CLB in the latest quarter, The investment management firm added 66 additional shares and now holds a total of 6,310 shares of Core Laboratories N.V. which is valued at $738,207. Core Laboratories N.V. makes up approx 0.07% of Cipher Capital Lp’s portfolio.American Century Companies Inc boosted its stake in CLB in the latest quarter, The investment management firm added 230 additional shares and now holds a total of 454,250 shares of Core Laboratories N.V. which is valued at $56.8 Million. Core Laboratories N.V. makes up approx 0.07% of American Century Companies Inc’s portfolio. Ramsey Quantitative Systems sold out all of its stake in CLB during the most recent quarter. The investment firm sold 7,801 shares of CLB which is valued $975,203.Aperio Group reduced its stake in CLB by selling 1,477 shares or 19.29% in the most recent quarter. The Hedge Fund company now holds 6,181 shares of CLB which is valued at $826,152. Core Laboratories N.V. makes up approx 0.01% of Aperio Group’s portfolio.
Core Laboratories N.V. opened for trading at $120.15 and hit $123.21 on the upside on Wednesday, eventually ending the session at $122.64, with a gain of 2.89% or 3.45 points. The heightened volatility saw the trading volume jump to 4,19,055 shares. Company has a market cap of $5,200 M.
On the company’s financial health, Core Laboratories N.V. reported $0.37 EPS for the quarter, based on the information available during the earnings call on Apr 20, 2016. Analyst had a consensus estimate of $0.37. The company had revenue of $153.65 million for the quarter, compared to analysts expectations of $156.67 million. The company’s revenue was down -28.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.86 EPS.
Many Wall Street Analysts have commented on Core Laboratories N.V.. Company shares were Reiterated by Cowen on Apr 22, 2016 to “Market Perform”, Firm has raised the Price Target to $ 105 from a previous price target of $80 .Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Outperform”, Firm has raised the Price Target to $ 137 from a previous price target of $128 .Core Laboratories N.V. was Initiated by Citigroup to “Neutral” on Feb 29, 2016.
Core Laboratories N.V. (Core Lab) is a provider of proprietary and patented reservoir description production enhancement and reservoir management services to the oil and gas industry. These services and products are directed toward enabling its clients to improve reservoir performance and increase oil and gas recovery from their producing fields. The Company operates in three segments: Reservoir Description Production Enhancement and Reservoir Management. The Company provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.